Roche, Celgene, BMS boast a place among orphan drug royalty

These days, the orphan drug business is a good place to win laurels. Which drugmakers are in line for the most impressive crowns? Multibillion-dollar blockbusters are expected from Celgene ($CELG), Roche ($RHHBY), Merck ($MRK) and Bristol-Myers ($BMY), to name a few. Report